Peak Performance Peptides vs Philips North America: FDA Enforcement Comparison

Philips North America has been the subject of 369 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for Peak Performance Peptides.

Peak Performance Peptides: 1 warning letter, 0 recalls, 0 approval records, 0 Form 483s.

Philips North America: 0 warning letters, 369 recalls, 0 approval records, 0 Form 483s.

Side by side

Peak Performance Peptides — Warning letters1

Philips North America — Warning letters0

Peak Performance Peptides — Recalls0

Philips North America — Recalls369

Peak Performance Peptides — Approval records0

Philips North America — Approval records0

Peak Performance Peptides — Form 483s0

Philips North America — Form 483s0

Timeline

Peak Performance Peptides

Most recent FDA action: August 24, 2026

Full history →

Philips North America

Most recent FDA action: October 7, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"Peak Performance Peptides vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed October 13, 2026. https://argushq.ai/compare/peak-performance-peptides-vs-philips-north-america

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗